Concept

Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

This study was a nationwide, population based study in Spain that utilized two-stage random sampling stratified by province and municipality size. From April 27 to May 11, 2020, 61,075 participants (75·1% of all contacted individuals within selected households) answered a questionnaire.

Seroprevalence was 5·0% (95% CI 4·7–5·4) by the point-of-care test and 4·6% (4·3–5·0) by immunoassay. There was substantial geographical variability, with higher prevalence around Madrid (>10%) and lower in coastal areas (<3%).

In 7273 individuals with anosmia or at least three symptoms, seroprevalence ranged from 15·3% (13·8–16·8) to 19·3% (17·7–21·0). Around a third of seropositive participants were asymptomatic, ranging from 21·9% (19·1–24·9) to 35·8% (33·1–38·5). Only 19·5% (16·3–23·2) of symptomatic participants who were seropositive by both the point-of-care test and immunoassay reported a previous PCR test.

0

1

Updated 2020-07-10

Tags

SARS-CoV-2 (COVID-19)

Biomedical Sciences